Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 2 |
2007 | 1 |
2009 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Diabetes Obes Metab. 2009 Jul;11(7):680-7. doi: 10.1111/j.1463-1326.2008.01024.x.
Diabetes Obes Metab. 2009.
PMID: 19527481
Clinical Trial.
RESULTS: There was no difference between BIAsp and BHI in geometric weighted average serum glucose over 24 h [7.3 vs. 7.7 mmol/l, BIAsp/BHI ratio 0.95 (95% CI 0.88-1.02), not significant (NS)], but daytime geometric weighted average glucose concentration was significantly …
RESULTS: There was no difference between BIAsp and BHI in geometric weighted average serum glucose over 24 h [7.3 vs. 7.7 mmol/l, BIA …
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.
Ashwell SG, et al.
Diabet Med. 2006 Mar;23(3):285-92. doi: 10.1111/j.1464-5491.2005.01781.x.
Diabet Med. 2006.
PMID: 16492212
Clinical Trial.
This was confirmed by an 8% lower 24-h plasma glucose area under the curve (AUC) (187 vs. 203 mmol l(-1) h(-1), P = 0.037), a 24% reduction in plasma glucose AUC > 7.0 mmol/l1 (47 vs. 62 mmol l(-1) h(-1), P = 0.017) and a 15% lower post-prandial plasma glucose AU …
This was confirmed by an 8% lower 24-h plasma glucose area under the curve (AUC) (187 vs. 203 mmol l(-1) h(-1), P = 0.037), a 24% red …
Item in Clipboard
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK, Sibal L, Ashwell SG, Home PD.
Dashora UK, et al.
Diabet Med. 2007 Apr;24(4):344-9. doi: 10.1111/j.1464-5491.2007.02094.x. Epub 2007 Jan 12.
Diabet Med. 2007.
PMID: 17298589
Clinical Trial.
RESEARCH DESIGN AND METHODS: In this 16-week, double-blind, placebo-controlled study, people with Type 2 diabetes [n = 55, HbA(1c) 8.2 +/- 1.0 (+/- sd)%, duration of diabetes 12.8 +/- 6.0 years, duration of insulin treatment 6.0 +/- 4.0 years] were transferred to single be …
RESEARCH DESIGN AND METHODS: In this 16-week, double-blind, placebo-controlled study, people with Type 2 diabetes [n = 55, HbA(1c) 8. …
Item in Clipboard
Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study.
Sibal L, Law HN, Gebbie J, Dashora UK, Agarwal SC, Home P.
Sibal L, et al.
Ann N Y Acad Sci. 2006 Nov;1084:191-207. doi: 10.1196/annals.1372.037.
Ann N Y Acad Sci. 2006.
PMID: 17151302
People who developed macrovascular complications were older (48 +/- 12 versus 36 +/- 11 [SD] years; P = 0.000), had longer duration of diabetes (28 +/- 12 versus 18 +/- 11 years; P = 0.000), higher BMI (26.7 +/- 4.6 versus 25.4 +/- 3.6 kg/m2; P = 0.041), higher base line serum ch …
People who developed macrovascular complications were older (48 +/- 12 versus 36 +/- 11 [SD] years; P = 0.000), had longer duration of diabe …
Item in Clipboard
Cite
Cite